Vasopressin: a new target for the treatment of heart failure

« Previous Next »American Heart Journal
Volume 146, Issue 1 , Pages 9-18, July 2003

Vasopressin: a new target for the treatment of heart failure☆

Craig R Lee, PharmD
- School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Michael L Watkins, PharmD
- GlaxoSmithKline, Research Triangle Park, NC, USA
J.Herbert Patterson, PharmD
- School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Departments of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Wendy Gattis, PharmD
- Duke Clinical Research Institute, Durham, NC, USA
Christopher M O’Connor, MD
- Duke Clinical Research Institute, Durham, NC, USA
Mihai Gheorghiade, MD
- Northwestern University Medical School, Chicago, Ill, USA
Kirkwood F Adams Jr, MD
- Departments of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Reprint requests: Kirkwood F. Adams, Jr, MD, Division of Cardiology, University of North Carolina at Chapel Hill, CB# 7075, 342 Burnett-Womack Building, Chapel Hill, NC 27599-7075, USA